Phosphaturic mesenchymal tumor-narrative review of the diagnostic challenges and modern treatment.
Abstract
Background
AND
Objective
Phosphaturic mesenchymal tumor (PMT) is a very rare form of mesenchymal neoplasm. Its distinctive paraneoplastic syndrome, tumor-induced osteomalacia (TIO), significantly impacts patients' quality of life and results in long-term health consequences. PMTs frequently remain undiagnosed for extended periods due to the absence of specific manifestations and the imaging and clinical characteristics of the tumor itself. At present, there is an absence of clear management guidelines, and the extant literature on PMT is limited. The purpose of this paper is, therefore, to compile available data on PMT and TIO for clinicians.
Methods
A narrative review was conducted, with a search of the PubMed, Web of Science and Scopus databases. KEY CONTENT AND
Findings
Recent advancements in the field of PMT have led to a more comprehensive understanding of the molecular mechanisms underlying tumor development. Specifically, the research has identified recurrent FN1-FGFR1 fusions as a major molecular driver of tumor development. Additionally, studies have highlighted the role of excessive fibroblast growth factor 23 (FGF23) production in disrupting phosphate homeostasis, resulting in osteomalacia, bone pain, fractures, and pseudofractures. Advanced functional imaging techniques remain crucial for PMT diagnosis, and the cornerstone of treatment is complete surgical resection, which is typically curative. However, the presentation of PMTs exhibits significant heterogeneity in clinical manifestations, histological characteristics, and imaging features. Clinicians often face challenges due to their limited experience with this very rare entity.
Conclusions
This review synthesizes the clinical presentation, pathological features, diagnostic strategies, molecular pathogenesis, and therapeutic options for PMTs, emphasizing contemporary challenges and future investigative directions.